Gooderham, M., L. Spelman, S. Imafuku, M. Romanelli, J. F. Merola, A. W. Armstrong, E. Colston, S. Banerjee, T. Scharnitz, and A. Blauvelt. “Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Efficacy by Baseline Demographic and Disease Characteristics in the Phase 3 POETYK PSO-1 and PSO-2 Trials”. SKIN The Journal of Cutaneous Medicine, vol. 7, no. 4, July 2023, p. s219, doi:10.25251/skin.7.supp.219.